- Theranos (THERA) has failed a second major U.S. regulatory inspection of its laboratory facilities, WSJ reports, a setback the Silicon Valley blood-testing firm hasn't disclosed to investors or patients.
- The failed regulatory inspection - at its one active lab at the time - has put the company at risk of a new round of sanctions and comes after it recruited a new technology advisory board.